← All trials
NCT03944447
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2018
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 100000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- OMNI Medical Services, LLCLead sponsor
- OMNI Medical Services, LLCOverall official - principal investigator
Drugs studied
Indications studied
- Chronic Traumatic Encephalopathy
- Brain Injuries, Traumatic
- COVID-19
- Amyotrophic Lateral Sclerosis
- Anemia, Sickle Cell
- Anxiety
- Autistic Disorder
- Bipolar Disorder
- Colitis, Ulcerative
- Crohn Disease
- Depression
- Epilepsy
- Fibromyalgia
- Tourette Syndrome
- Glaucoma
- Hepatitis C
- Sleep Initiation and Maintenance Disorders
- Multiple Sclerosis
- Opioid-Related Disorders
- Neoplasms
- Parkinson Disease
- Seizures
- Stress Disorders, Post-Traumatic
- Inflammatory Bowel Diseases
- HIV Infections
- Coronavirus
- Coronavirus Infections
- Severe Acute Respiratory Syndrome
- Chronic Pain
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.